TY - JOUR
AR - IJCST-2021-1-101
TI - Optimal Upfront CLL Treatment during the COVID-19 Pandemic
AU - Ezzat, Elhassadi
JO - International Journal of Cancer Science and Therapy
PY - 2021
DA - Wed 17, Mar 2021
SN - 
DO - http://dx.doi.org/10.31487/j.IJCST.2021.01.01
UR - https://www.sciencerepository.org/optimal-upfront-cll-treatment-during-the-covid-19-pandemic_IJCST-2021-1-101 
KW - COVID-19 & SARS CoV-2, pandemic, chronic lymphocytic leukemia, Ibrutinib
AB - The coronavirus disease 2019 (COVID-19) pandemic has challenged our healthcare systems and threatened individuals worldwide, particularly the most vulnerable elderly and those with medical comorbidities. The emergence of the new virus variant with its increased infectivity threats requires a quick response before the availability of evidence on managing patients with chronic lymphocytic leukemia (CLL) in this pandemic. Accordingly, this document prepared to provide informed opinions based on available evidence on how CLL patients were treated during the pandemic period.